tiprankstipranks
Trending News
More News >
Streamex (STEX)
NASDAQ:STEX
US Market
Advertisement

Streamex (STEX) AI Stock Analysis

Compare
398 Followers

Top Page

STEX

Streamex

(NASDAQ:STEX)

Select Model
Select Model
Select Model
Underperform 34 (OpenAI - 4o)
Rating:34Underperform
Price Target:
BioSig Technologies faces significant financial difficulties, with persistent losses, high leverage, and negative cash flow trends. While technical analysis indicates some short-term momentum, potential overbought conditions warrant caution. The negative P/E ratio further underscores valuation challenges and risks associated with the stock.

Streamex (STEX) vs. SPDR S&P 500 ETF (SPY)

Streamex Business Overview & Revenue Model

Company DescriptionBioSig Technologies, Inc. recently rebranded as Streamex Corp., effective September 12, 2025, following its merger with Streamex Exchange Corporation. The company shifted focus from healthcare technology to real-world asset tokenization, especially integrating the gold and commodities market into blockchain technology. Streamex provides institutional-grade infrastructure for tokenizing assets powered by a gold-denominated treasury.
How the Company Makes MoneyBioSig Technologies generates revenue primarily through the sale and lease of its PURE EP System to hospitals and medical institutions. The company also earns money by providing ongoing support services, including maintenance and upgrades, to ensure optimal performance of its systems. Additionally, BioSig may enter into strategic partnerships and collaborations with other healthcare entities and technology providers to expand its market reach and enhance its technological offerings. Key revenue streams include direct sales, leasing agreements, and service contracts associated with the PURE EP System.

Streamex Financial Statement Overview

Summary
Income Statement
10
Very Negative
Balance Sheet
20
Very Negative
Cash Flow
15
Very Negative
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Streamex Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price5.01
Price Trends
50DMA
5.15
Negative
100DMA
5.70
Negative
200DMA
3.38
Positive
Market Momentum
MACD
0.03
Positive
RSI
44.31
Neutral
STOCH
19.65
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STEX, the sentiment is Neutral. The current price of 5.01 is below the 20-day moving average (MA) of 5.82, below the 50-day MA of 5.15, and above the 200-day MA of 3.38, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 44.31 is Neutral, neither overbought nor oversold. The STOCH value of 19.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STEX.

Streamex Risk Analysis

Streamex disclosed 52 risk factors in its most recent earnings report. Streamex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Streamex Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
$10.57M0.42-499.57%-73.36%
48
Neutral
$23.49M-262.03%2.65%70.21%
45
Neutral
$18.97M-63.40%-91.14%9.47%
45
Neutral
$34.61M-329.16%15.00%71.57%
37
Underperform
-2.99%59.87%
34
Underperform
$192.23M-67.50%45.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
STEX
Streamex
5.01
4.69
1465.62%
AXDXQ
Accelerate Diagnostics
0.01
-1.75
-99.43%
CODX
Co-Diagnostics
0.38
-0.90
-70.31%
PAVM
PAVmed
0.49
-0.67
-57.76%
VVOS
Vivos Therapeutics
3.12
0.59
23.32%
ADGM
Adagio Medical Holdings
2.02
-0.80
-28.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 26, 2025